Involvement of ER-α36, Src, EGFR and STAT5 in the biphasic estrogen signaling of ER-negative breast cancer cells

Oncology Reports

Volumn 27, Issue 6, 2012, Pages 2057-2065

  Zhang, Xin Tian ^a   Ding, Ling ^b   Kang, Lian Guo ^a   Wang, Zhao Yi ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Biphasic response; EGFR; ER 36; ER negative breast cancer cells; Estrogen; Src; STAT5

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA36; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HORMONE ACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN D1; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; STAT5 TRANSCRIPTION FACTOR;

EID: 84860703449     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1722     Document Type: Article

References (38)

1. Nilsson S, Makela S, Treuter E, et al: Mechanisms of estrogen action. Physiol Rev 81: 1535-1565, 2001. (Pubitemid 32951806)
2. Kelly MJ and Levin ER: Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab 12: 152-156, 2001. (Pubitemid 33713555)
3. Segars JH and Driggers PH: Estrogen action and cytoplasmic signaling cascades. Part I: membrane-associated signaling complexes. Trends Endocrinol Metab 13: 349-354, 2002. (Pubitemid 36733951)
4. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y and Deuel TF: Identification, cloning, and expression of human estrogen receptor-α36, a novel variant of human estrogen receptor-α66. Biochem Biophys Res Commun 336: 1023-1027, 2005. (Pubitemid 41383424)
5. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y and Deuel TF: A variant of estrogen receptor-α, hER-α36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA 103: 9063-9068, 2006. (Pubitemid 43902533)
6. Zou Y, Ding L, Coleman M and Wang Z: Estrogen receptor-alpha (ER-α) suppresses expression of its variant ER-α36. FEBS Lett 583: 1368-1374, 2009.
7. Lee LM, Cao J, Deng H, Chen P, Gatalica Z and Wang ZY: ER-α36, a novel variant of ER-α, is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res 28: 479-483, 2008.
8. Shi L, Dong B, Li Z, et al: Expression of ER-α36, a novel variant of estrogen receptor α, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol 27: 3423-3429, 2009.
9. Vranic S, Gatalica Z, Deng H, et al: ER-α36, a novel isoform of ER-α66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast. J Clin Pathol 64: 54-57, 2011.
10. Zhang XT, Kang LG, Ding L, Vranic S, Gatalica Z and Wang ZY: A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene 30: 770-780, 2011.
11. vom Saal FS, Timms BG, Montano MM, et al: Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc Natl Acad Sci USA 94: 2056-2061, 1997. (Pubitemid 27113961)
12. Miodini P, Fioravanti L, Di Fronzo G and Cappelletti V: The two phyto-oestrogens genistein and quercetin exert different effects on oestrogen receptor function. Br J Cancer 80: 1150-1155, 1999. (Pubitemid 29264073)
13. Li L, Andersen ME, Heber S and Zhang Q: Non-monotonic dose-response relationship in steroid hormone receptor-mediated gene expression. J Mol Endocrinol 38: 569-585, 2007. (Pubitemid 47019060)
14. Calabrese EJ: Estrogen and related compounds: biphasic dose responses. Crit Rev Toxicol 31: 503-515, 2001.
15. Kuchler RJ and Grauer RC: Effects of natural estrogens on L strain fibroblasts in tissue culture. Proc Soc Exp Biol Med 110: 287-292, 1962.
16. Riley PA, Latter A and Sutton PM: Reversible morphological changes in human breast fibroblasts exposed to stilboestrol. Eur J Cancer 14: 579-586, 1978. (Pubitemid 8336078)
17. Hass R and Sohn C: Effects of estrogen on cell cycle progression and associated metabolic pathways in normal and tumorigenic breast cells. Signal Transduction 3: 9-16, 2003. (Pubitemid 37392180)
18. Rao PN and Engelberg J: Structural specificity of estrogens in the induction of mitotic chromatid non-disjunction in HeLa cells. Exp Cell Res 48: 71-81, 1967.
19. Tsutsui T, Maizumi H, McLachlan JA and Barrett JC: Aneuploidy induction and cell transformation by diethylstilbestrol: a possible chromosomal mechanism in carcinogenesis. Cancer Res 43: 3814-3821, 1983. (Pubitemid 13077710)
20. Watson CS, Jeng YJ and Kochukov MY: Nongenomic signaling pathways of estrogen toxicity. Toxicol Sci 115: 1-11, 2010.
21. Wolf DM and Jordan VC: A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results Cancer Res 127: 23-33, 1993.
22. Yao K, Lee ES, Bentrem DJ, et al: Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 6: 2028-2036, 2000. (Pubitemid 30305102)
23. Osipo C, Gajdos C, Liu H, Chen B and Jordan VC: Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst 95: 1597-1608, 2003. (Pubitemid 37455927)
24. Song RX, Mor G, Naftolin F, et al: Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17β-estradiol. J Natl Cancer Inst 93: 1714-1723, 2001. (Pubitemid 33130260)
25. Lewis JS, Osipo C, Meeke K and Jordan VC: Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol 94: 131-141, 2005. (Pubitemid 40614526)
26. Lewis JS, Meeke K, Osipo C, et al: Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 97: 1746-1759, 2005. (Pubitemid 41782284)
27. Fox EM, Bernaciak TM, Wen J, Weaver AM, Shupnik MA and Silva CM: Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells. Mol Endocrinol 22: 1781-1796, 2008.
28. Yamashita H, Iwase H, Toyama T and Fujii Y: Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells. Oncogene 22: 1638-1652, 2003. (Pubitemid 36408179)
29. Brockman JL, Schroeder MD and Schuler LA: PRL activates the cyclin D1 promoter via the Jak2/Stat pathway. Mol Endocrinol 16: 774-784, 2002. (Pubitemid 34297746)
30. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 339: 1-15, 1992.
31. Nissen-Meyer R: 'Prophylactic' ovariectomy and ovarian irradiation in breast cancer. Acta Unio Int Contra Cancrum 20: 527-530, 1964.
32. Narod SA: Hormonal prevention of hereditary breast cancer. Ann NY Acad Sci 952: 36-43, 2001.
33. Rebbeck TR, Levin AM, Eisen A, et al: Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91: 1475-1479, 1999. (Pubitemid 29424552)
34. Tsai EM, Wang SC, Lee JN and Hung MC: Akt activation by estrogen in estrogen receptor-negative breast cancer cells. Cancer Res 61: 8390-8392, 2001.
35. Friedl A and Jordan VC: Oestradiol stimulates growth of oestrogen receptor-negative MDA-MB-231 breast cancer cells in immunodeficient mice by reducing cell loss. Eur J Cancer 30A: 1559-1564, 1994. (Pubitemid 24343022)
36. Nomoto S, Arao Y, Horiguchi H, Ikeda K and Kayama F: Oestrogen causes G2/M arrest and apoptosis in breast cancer cells MDA-MB-231. Oncol Rep 9: 773-776, 2002.
37. Chong YP, Mulhern TD and Cheng HC: C-terminal Src kinase (CSK) and CSK-homologous kinase (CHK) - endogenous negative regulators of Src-family protein kinases. Growth Factors 23: 233-244, 2005. (Pubitemid 43203054)
38. Playford MP and Schaller MD: The interplay between Src and integrins in normal and tumor biology. Oncogene 23: 7928-7946, 2004. (Pubitemid 39468852)